Abstract
Background: Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide. HCC patients have a poor prognosis due to shortage of effective therapies though a small proportion of patients are eligible for curative treatments. Precision medicine, a recently emerging medicinal model, has provided more avenues in the management of HCC.
Methods: Published literatures related to HCC and precision medicine were reviewed. The article aims to discuss the recent progress of HCC therapy under the guidance of precision medicine, and the major obstacles for its application.
Results: Sorafenib remains the only first-line drug proved for treating advanced HCC, though it displays limited beneficial effects. Advances have been achieved in the technologies of new generation sequencing and molecular biology, bioinformatics, big data and cloud computing frame. Recent progresses in seeking tumor biomarkers and oncogenic addiction loops, re-analyses of failed clinical trials, techniques of circulating tumor cells and liquid biopsy, new clinical designs based on molecular information have offered a glimmer of hope in combating HCC. However, there are many obstacles, such as high heterogeneity, unpredictable driver genes, oncogenetic addiction loops and actionable events and drug resistance.
Conclusion: The future progress in interdisciplinary application of computing, mathematics and information in medicine may further promote the development of precision medicine in the prevention, diagnosis, treatment and monitoring of HCC. We hope this article can provide some new clues for clinicians and scientists engaged in the clinical and basic research of HCC.
Keywords: Hepatocellular carcinoma, precision medicine, personalized medicine, sorafenib, bioinformatics, tumor biomarkers.
Graphical Abstract
Clinical Cancer Drugs
Title:Progress and Obstacles in the Application of Precision Medicine in the Management of Hepatocellular Carcinoma
Volume: 4
Author(s): Ping Wang and Xueying Sun*
Affiliation:
- The Hepatosplenic Surgery Center, Department of General Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin 150001,China
Keywords: Hepatocellular carcinoma, precision medicine, personalized medicine, sorafenib, bioinformatics, tumor biomarkers.
Abstract: Background: Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide. HCC patients have a poor prognosis due to shortage of effective therapies though a small proportion of patients are eligible for curative treatments. Precision medicine, a recently emerging medicinal model, has provided more avenues in the management of HCC.
Methods: Published literatures related to HCC and precision medicine were reviewed. The article aims to discuss the recent progress of HCC therapy under the guidance of precision medicine, and the major obstacles for its application.
Results: Sorafenib remains the only first-line drug proved for treating advanced HCC, though it displays limited beneficial effects. Advances have been achieved in the technologies of new generation sequencing and molecular biology, bioinformatics, big data and cloud computing frame. Recent progresses in seeking tumor biomarkers and oncogenic addiction loops, re-analyses of failed clinical trials, techniques of circulating tumor cells and liquid biopsy, new clinical designs based on molecular information have offered a glimmer of hope in combating HCC. However, there are many obstacles, such as high heterogeneity, unpredictable driver genes, oncogenetic addiction loops and actionable events and drug resistance.
Conclusion: The future progress in interdisciplinary application of computing, mathematics and information in medicine may further promote the development of precision medicine in the prevention, diagnosis, treatment and monitoring of HCC. We hope this article can provide some new clues for clinicians and scientists engaged in the clinical and basic research of HCC.
Export Options
About this article
Cite this article as:
Wang Ping and Sun Xueying *, Progress and Obstacles in the Application of Precision Medicine in the Management of Hepatocellular Carcinoma, Clinical Cancer Drugs 2017; 4 (2) . https://dx.doi.org/10.2174/2212697X04666170817125451
DOI https://dx.doi.org/10.2174/2212697X04666170817125451 |
Print ISSN 2212-697X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-6988 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
TP73, An Under-Appreciated Player in Non-Hodgkin Lymphoma Pathogenesis and Management
Current Molecular Medicine Modulation of the Type I Interferon Response Defines the Sensitivity of Human Melanoma Cells to Oncolytic Measles Virus
Current Gene Therapy Targeting Angiogenesis in Thyroid Cancer
Current Angiogenesis (Discontinued) MicroRNA-31 Inhibits Lung Adenocarcinoma Stem-Like Cells via Down-Regulation of MET-PI3K-Akt Signaling Pathway
Anti-Cancer Agents in Medicinal Chemistry Chemoprotective Mechanism of the Natural Compounds, Epigallocatechin- 3-O-Gallate, Quercetin and Curcumin Against Cancer and Cardiovascular Diseases
Current Medicinal Chemistry Understanding Epithelial-Mesenchymal Transition may Reveal Novel Therapeutic Targets for Oral Squamous Cell Carcinoma
Current Cancer Therapy Reviews Drug Induced Cutaneous Manifestations due to Treatment of Gastrointestinal Disorders
Current Drug Metabolism An Overview on COVID-19 and its Effect on Cardiovascular Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Combinatorial Application of Nucleic Acid-Based Agents Targeting Protein Kinases for Cancer Treatment
Current Pharmaceutical Design Recombinant Snake Venom Cystatin Inhibits Tumor Angiogenesis in vitro and in vivo Associated with Downregulation of VEGF-A165, Flt-1 and bFGF
Anti-Cancer Agents in Medicinal Chemistry Dynamic Contrast-Enhanced MRI in Oncology Drug Development
Current Clinical Pharmacology Viral Based Gene Therapy for Prostate Cancer
Current Gene Therapy Periodontitis and Periodontal Disease - Innovative Strategies for Reversing the Chronic Infectious and Inflammatory Condition by Natural Products
Current Pharmaceutical Design Regulation of Tumor Angiogenesis by the Immune System
Current Angiogenesis (Discontinued) Small-Molecule Inhibitors of Bcl-2 Family Proteins as Therapeutic Agents in Cancer
Recent Patents on Anti-Cancer Drug Discovery Antioxidant, Pro-Oxidant and Other Biological Activities of Sesquiterpenes
Current Topics in Medicinal Chemistry Targeted Therapies in Combination with Radiotherapy in Oesophageal and Gastroesophageal Carcinoma
Current Medicinal Chemistry Emerging Strategies to Strengthen the Anti-Tumour Activity of Type I Interferons: Overcoming Survival Pathways
Current Cancer Drug Targets Regulation of Hypoxia-inducible Factor-1α and Vascular Endothelial Growth Factor Signaling by Plant Flavonoids
Mini-Reviews in Medicinal Chemistry Histone Deacetylase Inhibitors in Cancer Therapy: New Compounds and Clinical Update of Benzamide-Type Agents
Current Topics in Medicinal Chemistry